• Nabin K. Shrestha
  • Gary W. Procop
Part of the Molecular Pathology Library book series (MPLB, volume 1)


This chapter begins with a general description of the etiology, pathogenesis, pathology, clinical features, and diagnosis of bacterial pneumonia. Specifics of pathogenesis, clinical features, antibiotic resistance, and diagnostic testing for the important bacterial causes of community-acquired pneumonia are then discussed.


Lower Respiratory Tract Infection Mycoplasma Pneumoniae Bordetella Pertussis Moraxella Catarrhalis Mycoplasma Hominis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    White NJ. Melioidosis. Lancet 2003;361(9370):1715–1722.CrossRefPubMedGoogle Scholar
  2. 2.
    Parker NR, Barralet JH, Bell AM. Q fever. Lancet 2006;367(9511):679–888.CrossRefPubMedGoogle Scholar
  3. 3.
    Rotz LD, Khan AS, Lillibridge SR, et al. Public health assessment of potential biological terrorism agents. Emerg Infect Dis 2002;8(2):225–230.CrossRefPubMedGoogle Scholar
  4. 4.
    Husain AN, Kumar V. The Lung. In Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease, 7th ed. Philadelphia: Elsevier Saunders; 2005:711–772.Google Scholar
  5. 5.
    Moore-Gillon J. The Respiratory System. In Swash M, ed. Hutchison’s Clinical Methods, 21st ed. London: Elsevier Saunders; 2002:60–78.Google Scholar
  6. 6.
    Reimer LG, Carroll KC. Role of the microbiology laboratory in the diagnosis of lower respiratory tract infections. Clin Infect Dis 1998;26(3):742–748.CrossRefPubMedGoogle Scholar
  7. 7.
    Stralin K, Tornqvist E, Kaltoft MS, et al. Etiologic diagnosis of adult bacterial pneumonia by culture and PCR applied to respiratory tract samples. J Clin Microbiol 2006;44(2):643–645.CrossRefPubMedGoogle Scholar
  8. 8.
    Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis 2005;41(10):1438–1444.CrossRefPubMedGoogle Scholar
  9. 9.
    Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev 2001;65(2):187–207.CrossRefPubMedGoogle Scholar
  10. 10.
    Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998;27(4):764–770.CrossRefPubMedGoogle Scholar
  11. 11.
    Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med 2004;117Suppl 3A:3S–15S.PubMedGoogle Scholar
  12. 12.
    Kalin M, Lindberg AA. Diagnosis of pneumococcal pneumonia: a comparison between microscopic examination of expectorate, antigen detection and cultural procedures. Scand J Infect Dis 1983;15(3):247–255.PubMedGoogle Scholar
  13. 13.
    Murdoch DR. Molecular genetic methods in the diagnosis of lower respiratory tract infections. APMIS 2004;112(11–12):713–727.CrossRefPubMedGoogle Scholar
  14. 14.
    Rao VK, Krasan GP, Hendrixson DR, et al. Molecular determinants of the pathogenesis of disease due to nontypable Haemophilus influenzae. FEMS Microbiol Rev 1999;23(2):99–129.PubMedGoogle Scholar
  15. 15.
    Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001;14(2):336–363.CrossRefPubMedGoogle Scholar
  16. 16.
    Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001;32Suppl 2:S81–S93.CrossRefPubMedGoogle Scholar
  17. 17.
    Williams JD, Moosdeen F. Antibiotic resistance in Haemophilus influenzae: epidemiology, mechanisms, and therapeutic possibilities. Rev Infect Dis 1986;8Suppl 5:S555–S61.PubMedGoogle Scholar
  18. 18.
    Ehrhardt AF, Russo R. Clinical resistance encountered in the respiratory surveillance program (RESP) study: a review of the implications for the treatment of communityacquired respiratory tract infections. Am J Med 2001;111Suppl 9A:30S–38S.CrossRefPubMedGoogle Scholar
  19. 19.
    Then RL. Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole. Rev Infect Dis 1982;4(2):261–269.PubMedGoogle Scholar
  20. 20.
    Daly JA, Clifton NL, Seskin KC, Gooch WM 3rd. Use of rapid, nonradioactive DNA probes in culture confirmation tests to detect Streptococcus agalactiae, Haemophilus influenzae, and Enterococcus spp. from pediatric patients with significant infections. J Clin Microbiol 1991;29(1):80–82.PubMedGoogle Scholar
  21. 21.
    Marty A, Greiner O, Day PJ, et al. Detection of Haemophilus influenzae type b by real-time PCR. J Clin Microbiol 2004;42(8):3813–3815.CrossRefPubMedGoogle Scholar
  22. 22.
    Bootsma HJ, van der Heide HG, van de Pas S, et al. Analysis of Moraxella catarrhalis by DNA typing: evidence for a distinct subpopulation associated with virulence traits. J Infect Dis 2000;181(4):1376–1387.CrossRefPubMedGoogle Scholar
  23. 23.
    Karalus R, Campagnari A. Moraxella catarrhalis: a review of an important human mucosal pathogen. Microbes Infect 2000;2(5):547–559.CrossRefPubMedGoogle Scholar
  24. 24.
    Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens—findings of the Alexander Project 1992–1996. J Chemother 1999;11(Suppl 1):5–21.PubMedGoogle Scholar
  25. 25.
    Bootsma HJ, van Dijk H, Vauterin P, et al. Genesis of BRO beta-lactamase-producing Moraxella catarrhalis: evidence for transformation-mediated horizontal transfer. Mol Microbiol 2000;36(1):93–104.CrossRefPubMedGoogle Scholar
  26. 26.
    Greiner O, Day PJ, Altwegg M, Nadal D. Quantitative detection of Moraxella catarrhalis in nasopharyngeal secretions by real-time PCR. J Clin Microbiol 2003;41(4):1386–1390.CrossRefPubMedGoogle Scholar
  27. 27.
    Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37(11):1405–1433.CrossRefPubMedGoogle Scholar
  28. 28.
    Fliermans CB, Cherry WB, Orrison LH, et al. Ecological distribution of Legionella pneumophila. Appl Environ Microbiol 1981;41(1):9–16.PubMedGoogle Scholar
  29. 29.
    Rogers J, Keevil CW. Immunogold and fluorescein immunolabelling of Legionella pneumophila within an aquatic biofilm visualized by using episcopic differential interference contrast microscopy. Appl Environ Microbiol 1992;58(7):2326–2330.PubMedGoogle Scholar
  30. 30.
    Fields BS, Benson RF, Besser RE. Legionella and Legionnaires’ disease: 25 years of investigation. Clin Microbiol Rev 2002;15(3):506–526.CrossRefPubMedGoogle Scholar
  31. 31.
    Roig J, Rello J. Legionnaires’ disease: a rational approach to therapy. J Antimicrob Chemother 2003;51(5):1119–1129.CrossRefPubMedGoogle Scholar
  32. 32.
    Breiman RF, Butler JC. Legionnaires’ disease: clinical, epidemiological, and public health perspectives. Semin Respir Infect 1998;13(2):84–89.PubMedGoogle Scholar
  33. 33.
    Hayden RT, Uhl JR, Qian X, et al. Direct detection of Legionella species from bronchoalveolar lavage and open lung biopsy specimens: comparison of LightCycler PCR, in situ hybridization, direct fluorescence antigen detection, and culture. J Clin Microbiol 2001;39(7):2618–2626.CrossRefPubMedGoogle Scholar
  34. 34.
    Grayston JT, Diwan VK, Cooney M, Wang SP. Community-and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically. Arch Intern Med 1989;149(1):169–173.CrossRefPubMedGoogle Scholar
  35. 35.
    Schmidt SM, Muller CE, Mahner B, Wiersbitzky SK. Prevalence, rate of persistence and respiratory tract symptoms of Chlamydia pneumoniae infection in 1211 kindergarten and school age children. Pediatr Infect Dis J 2002;21(8):758–762.CrossRefPubMedGoogle Scholar
  36. 36.
    Hammerschlag MR. Chlamydia pneumoniae and the lung. Eur Respir J 2000;16(5):1001–1007.CrossRefPubMedGoogle Scholar
  37. 37.
    McConnell CT Jr, Plouffe JF, File TM, et al. Radiographic appearance of Chlamydia pneumoniae (TWAR strain) respiratory infections. CBPIS Study Group. Community-Based Pneumonia Incidence Study. Radiology 1994;192(3):819–24.PubMedGoogle Scholar
  38. 38.
    Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001;33(4):492–503.CrossRefPubMedGoogle Scholar
  39. 39.
    Wilson MH, Collier AM. Ultrastructural study of Mycoplasma pneumoniae in organ culture. J Bacteriol 1976;125(1):332–339.PubMedGoogle Scholar
  40. 40.
    Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;17(4):697–728.CrossRefPubMedGoogle Scholar
  41. 41.
    Collier AM. Attachment by mycoplasmas and its role in disease. Rev Infect Dis 1983;5(Suppl 4):S685–S691.PubMedGoogle Scholar
  42. 42.
    Meseguer MA, Perez-Molina JA, Fernandez-Bustamante J, et al. Mycoplasma pneumoniae pericarditis and cardiac tamponade in a ten-year-old girl. Pediatr Infect Dis J 1996;15(9):829–831.CrossRefPubMedGoogle Scholar
  43. 43.
    Abramovitz P, Schvartzman P, Harel D, et al. Direct invasion of the central nervous system by Mycoplasma pneumoniae: a report of two cases. J Infect Dis 1987;155(3):482–487.PubMedGoogle Scholar
  44. 44.
    Foy HM, Grayston JT, Kenny GE, et al. Epidemiology of Mycoplasma pneumoniae infection in families. JAMA 1966;197(11):859–866.CrossRefPubMedGoogle Scholar
  45. 45.
    Taylor-Robinson D, Webster AD, Furr PM, Asherson GL. Prolonged persistence of Mycoplasma pneumoniae in a patient with hypogammaglobulinaemia. J Infect 1980;2(2):171–175.CrossRefPubMedGoogle Scholar
  46. 46.
    Waites KB, Crabb DM, Duffy LB. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. Int J Antimicrob Agents 2003;21(6):574–577.CrossRefPubMedGoogle Scholar
  47. 47.
    Roberts MC, Koutsky LA, Holmes KK, et al. Tetracyclineresistant Mycoplasma hominis strains contain streptococcal tetM sequences. Antimicrob Agents Chemother 1985;28(1):141–143.PubMedGoogle Scholar
  48. 48.
    Ieven M, Ursi D, Van Bever H, et al. Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J Infect Dis 1996;173(6):1445–1452.PubMedGoogle Scholar
  49. 49.
    Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin Microbiol Infect 2003;9(4):263–273.CrossRefPubMedGoogle Scholar
  50. 50.
    Razin S. DNA probes and PCR in diagnosis of mycoplasma infections. Mol Cell Probes 1994;8(6):497–511.CrossRefPubMedGoogle Scholar
  51. 51.
    Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996.Clin Infect Dis1999;28(6):1230–1237.CrossRefPubMedGoogle Scholar
  52. 52.
    Schellekens J, von Konig CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J 2005;24(5 Suppl):S19–S24.PubMedGoogle Scholar
  53. 53.
    Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18(2):326–382.CrossRefPubMedGoogle Scholar
  54. 54.
    Locht C, Antoine R, Jacob-Dubuisson F. Bordetella pertussis, molecular pathogenesis under multiple aspects. Curr Opin Microbiol 2001;4(1):82–89.CrossRefPubMedGoogle Scholar
  55. 55.
    Jenkinson D. Natural course of 500 consecutive cases of whooping cough: a general practice population study. BMJ 1995;310(6975):299–302.PubMedGoogle Scholar
  56. 56.
    Ewanowich CA, Chui LW, Paranchych MG, et al. Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-antibody and culture results by using polymerase chain reaction methodology. J Clin Microbiol 1993;31(7):1715–1725.PubMedGoogle Scholar
  57. 57.
    Loeffelholz MJ, Thompson CJ, Long KS, Gilchrist MJ. Comparison of PCR, culture, and direct fluorescent-antibody testing for detection of Bordetella pertussis. J Clin Microbiol 1999;37(9):2872–2876.PubMedGoogle Scholar
  58. 58.
    Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5(5):275–286.CrossRefPubMedGoogle Scholar
  59. 59.
    Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29(5):1128–1132.CrossRefPubMedGoogle Scholar
  60. 60.
    Fey PD, Said-Salim B, Rupp ME, et al. Comparative molecular analysis of community-or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(1):196–203.CrossRefPubMedGoogle Scholar
  61. 61.
    Palavecino E. Community-acquired methicillin-resistant Staphylococcus aureus infections. Clin Lab Med 2004;24(2):403–418.CrossRefPubMedGoogle Scholar
  62. 62.
    Kuehnert MJ, Doyle TJ, Hill HA, et al. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis 2003;36(3):328–336.CrossRefPubMedGoogle Scholar
  63. 63.
    Karwa M, Currie B, Kvetan V. Bioterrorism: preparing for the impossible or the improbable. Crit Care Med 2005;33(1 Suppl):S75–S95.CrossRefPubMedGoogle Scholar
  64. 64.
    Greenfield RA, Bronze MS. Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents. Drug Discov Today 2003;8(19):881–888.CrossRefPubMedGoogle Scholar
  65. 65.
    Lim DV, Simpson JM, Kearns EA, Kramer MF. Current and developing technologies for monitoring agents of bioterrorism and biowarfare. Clin Microbiol Rev 2005;18(4):583–607.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Nabin K. Shrestha
    • 1
  • Gary W. Procop
    • 2
  1. 1.Department of Infectious DiseasesCleveland ClinicClevelandUSA
  2. 2.Clinical Microbiology, Department of Clinical PathologyCleveland ClinicClevelandUSA

Personalised recommendations